New Published Data Show Pluristem's PLX Cells Protect

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
New Published Data Show Pluristem's PLX Cells Protect Neurons

HAIFA, Israel, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq: PSTI ) (TASE: PSTI ), a leading developer of placenta-based cell therapy products, announced today that a study of PLacental eXpanded (PLX) cells was accepted for publication in the February, 2015 issue of Biochimica et Biophysica Acta Molecular Cell Research. The study results show that PLX cells protect PC12 cells – an established model of various nerve cells including dopaminergic neurons – from death after oxygen and glucose deprivation. The protective effects of PLX cells were strongly correlated with the secretion of interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF), which are known to have neuroprotective effects in humans with injuries to the nervous system that can occur after events such as a stroke.

"Our findings suggest that PLX cells may potentially treat damaged nerves, and may corroborate and explain the mechanism that leads to one of our findings in our Phase I trial in critical limb ischemia. In that study, patients treated with PLX cells had a statistically significant reduction in pain as compared to their baseline. An earlier preclinical study, published in the journal Brain Research , showed that PLX cells may effectively treat ischemic stroke," stated Pluristem CEO Zami Aberman.

Aberman continued, "These latest findings also call to mind two earlier preclinical studies , which indicated that PLX cells may be an effective treatment for both neuropathic and inflammatory nerve pain, suggesting that PLX cells could be a potential treatment for chronic nerve pain resulting from conditions such as diabetic neuropathy."

The study, titled "Human PLacental eXpanded (PLX) mesenchymal-like adherent stromal cells confer neuroprotection to nerve growth factor (NGF)-differentiated PC12 cells exposed to ischemia by secretion of IL-6 and VEGF", was conducted jointly by researchers at Pluristem and Prof. Philip Lazarovici, Jacob Gitlin Chair in Physiology and Pharmacology at the School of Pharmacy Institute for Drug Research at the Hebrew University and co-authored by Prof. Ephraim Yavin of the Department of Neurobiology at the Weizmann Institute of Science. The study was supported by the Magnet program of Israel's Ministry of Economy.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, hematological disorders, radiation damage, and ischemia. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com , the content of which is not part of this press release.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, forward-looking statements are used in this press release when we discuss the potential of PLX cells to treat damaged nerves and to treat ischemic stroke, and the potential of PLX cells to be an effective treatment for both neuropathic and inflammatory nerve pain. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or that historic results would not be interpreted differently in light of additional research and clinical and preclinical trials results. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Pluristem Therapeutics Inc.: Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 0

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 18

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 19

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 370

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 358

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 81

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading

Top 5 Most Recently Viewed Articles

BETR Faces Securities Fraud Actions Post-Misleading Statements

Updated Category News Views 123

Unpacking the Legal Drama Around BETR The tale of Better Home & Finance Holding Company (BETR) is like a roadside crash you can't help but stare at. We're talking big, ugly losses and a chance for investors who got roughed up to throw some punches back with a securities fraud class action. The legal honchos at Howard G. Smith's law office are rallying the troops. If...

Continue Reading
Dorian LPG Faces Market Challenges But Holds Strong Financials

Updated Category News Views 133

Dorian LPG Stock Performance Overview In a challenging market environment, Dorian LPG Ltd. (NYSE: LPG) stock has recently touched a 52-week low, with shares falling to $24.86. This significant drop highlights a broader trend in the industry, as the company grapples with headwinds leading to a troubling one-year change of -38.78%. Investors are closely monitoring the stock...

Continue Reading
Copenhagen Airports A/S Annual General Meeting Announcement

Updated Category News Views 115

Upcoming Annual General Meeting of Copenhagen Airports A/S Shareholders are invited to participate in the Annual General Meeting of Copenhagen Airports A/S. This important event will take place on the scheduled date and time, providing an opportunity for stakeholders to engage with the management and stay informed about the company's direction. Notice of Meeting Details...

Continue Reading
Important Notice for Shareholders of KinderCare Learning

Updated Category News Views 131

Key Notice for KinderCare Learning Companies, Inc. Shareholders The Gross Law Firm has issued a crucial notice directed at shareholders of KinderCare Learning Companies, Inc. (NYSE: KLC) regarding a class action lawsuit. This communication is particularly relevant to those who acquired shares during the designated class period. Shareholders are strongly encouraged to make...

Continue Reading
Discover the New Romantic Getaway at Cicada Resort Bali Ubud

Updated Category News Views 350

Welcome to Cicada Resort Bali Ubud Cicada Resort Bali Ubud, Autograph Collection, located in Sebatu's tranquil environment, extends a warm invitation to travelers seeking a romantic retreat. The resort has recently become part of the prestigious Autograph Collection, contributing to its expanding presence in the hospitality space. Embrace Nature and Culture Just a short...

Continue Reading